The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.442%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
7th Mar 20197:00 amRNSAkili & Shionogi Deal in Taiwan/Japan $20M upfront
5th Mar 20197:00 amRNSKaruna Appoints Chief Financial Officer
22nd Feb 20194:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:36 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSPRTC to Present at Two US Investor Conferences
15th Feb 20194:41 pmRNSSecond Price Monitoring Extn
15th Feb 20194:35 pmRNSPrice Monitoring Extension
14th Feb 20197:00 amRNSVor Raises $42M to Advance Leukaemia Treatment
28th Jan 20197:00 amRNSAlivio Partners to Advance Non-opioid Pain Therapy
23rd Jan 20196:08 pmRNSVedanta Immuno-oncology Candidate Published
2nd Jan 20197:00 amRNSTotal Voting Rights
28th Dec 201812:07 pmRNSSecond Price Monitoring Extn
28th Dec 201812:02 pmRNSPrice Monitoring Extension
24th Dec 20187:00 amRNSVedanta Biosciences Raise $27M Series C Financing
17th Dec 20187:00 amRNSVedanta Initiates Phase 2 Study for Lead Candidate
10th Dec 20187:00 amRNSVedanta & BMS Immuno-Oncology Collaboration
28th Nov 20187:00 amRNSVor Granted First-in-class Immuno-oncology Patent
27th Nov 20187:00 amRNSJanssen/Vedanta Phase 1 in IBD & $12M Milestone
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
22nd Nov 201812:07 pmRNSSecond Price Monitoring Extn
22nd Nov 201812:02 pmRNSPrice Monitoring Extension
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:07 pmRNSSecond Price Monitoring Extn
14th Nov 201812:02 pmRNSPrice Monitoring Extension
13th Nov 201811:05 amRNSFull Gelesis Data Published in the Journal Obesity
7th Nov 20187:00 amRNSPRTC to Present at Jefferies 2018 in London
6th Nov 20181:00 pmRNSVedanta Presents Data on Immuno-Oncology Candidate
5th Nov 20187:00 amRNSGelesis to Present Full Data for Lead Candidate
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
17th Oct 20187:00 amRNSKaruna Adds Sage Therapeutics CEO to Board
16th Oct 201812:20 pmRNSresTORbio Announces Additional Positive Ph 2b Data
15th Oct 20187:00 amRNSKaruna Initiates Phase 2 Study in Schizophrenia
4th Oct 20187:00 amRNSVedanta Announces Successful Ph1 Clinical Results
17th Sep 20184:15 pmRNSBrain Lymphatics Published in Nature Neuroscience
12th Sep 201812:00 pmRNSAkili Exclusively Licenses New Digital Technology
12th Sep 20187:00 amRNSAlivio Awarded $3.3M Grant from US Dept of Defense
11th Sep 20187:00 amRNSPureTech Health plc - Half-Year Report
7th Sep 20184:40 pmRNSSecond Price Monitoring Extn
7th Sep 20184:35 pmRNSPrice Monitoring Extension
5th Sep 20187:00 amRNSVedanta Adds Fmr Janssen Immunology Head to Board
29th Aug 20187:00 amRNSNotice of Results
15th Aug 201811:00 amRNSPureTech's Karuna Appoints Steven Paul, MD, as CEO
9th Aug 20187:01 amRNSPureTech's Akili Expands Series C Funding to $68M
2nd Aug 20187:00 amRNSPureTech's Karuna Completes $42M Financing
1st Aug 20185:30 pmRNSTotal Voting Rights
26th Jul 20187:00 amRNSBrain Lymphatics Programme Published in Nature
25th Jul 201812:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.